Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 9:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 362 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Reference product Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

GSK1325756 Relative Bioavailability Study in Healthy Elderly Subjects

NCT03457727
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Danirixin, Omeprazole
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 31, 2026, 9:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Clinical Trial to Evaluate Efficacy and Safety of a Water-soluble Head Lice Product.

NCT03617926
View directory record Official record
Conditions
Head Lice, Pediculosis Capitis
Interventions
X92001666, RID shampoo
Device · Other
Lead sponsor
Oystershell NV
Industry
Eligibility
2 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Miami, Florida • Plantation, Florida
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Oct 31, 2026, 9:21 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

NCT01153009
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Vortioxetine, Duloxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
56
States / cities
Beverly Hills, California • Chino, California • Garden Grove, California + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 31, 2026, 9:21 AM EDT
Recruiting Phase 2 Interventional

Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT04606914
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube, Primary Peritoneal Cancer
Interventions
mirvetuximab soravtansine (MIRV; IMGN853)
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
9
States / cities
Birmingham, Alabama • San Francisco, California • Minneapolis, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 31, 2026, 9:21 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis

NCT03824912
View directory record Official record
Conditions
Tinea Pedis
Interventions
Ketoconazole Cream 2%, Ketoconazole Cream 2% (G&W Laboratories Inc.), Placebo
Drug
Lead sponsor
Encube Ethicals Pvt. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
831 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Long Beach, California • Miami, Florida • Miami Lakes, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 31, 2026, 9:21 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Study of Virtually Supervised Mouth Rinses and Flossing

NCT05600231
View directory record Official record
Conditions
Healthy
Interventions
LISTERINE COOL MINT Antiseptic Mouthwash, LISTERINE COOL MINT ZERO Alcohol Mouthwash, Reach Unflavored Waxed Dental Floss, Colgate Cavity Protection Toothpaste
Other
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 31, 2026, 9:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extended-Release Tablet

NCT01758978
View directory record Official record
Conditions
Pain
Interventions
a 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B).
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Oct 31, 2026, 9:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Non-Fasted Conditions

NCT01344369
View directory record Official record
Conditions
Healthy
Interventions
Norethindrone/Ethinyl Estradiol, FEMCON® Fe
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Oct 31, 2026, 9:21 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Adapalene Gel 0.1% and to Differin Gel in the Treatment of Acne Vulgaris

NCT04797793
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene Gel 0.1%, Placebo Control, Differin® Gel (Adapalene 0.1%, Galderma)
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
978 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 31, 2026, 9:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Fasting Conditions

NCT01340625
View directory record Official record
Conditions
Bioequivalence
Interventions
Norethindrone/Ethinyl Estradiol, Ovcon® 35 Fe
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated May 25, 2011 · Synced Oct 31, 2026, 9:21 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Generic Tazarotene Cream, 0.05% for the Treatment of Plaque Psoriasis

NCT02160665
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Tazarotene Cream, 0.05%, Vehicle, Reference: Tazorac Cream, 0.05%
Drug
Lead sponsor
G & W Laboratories Inc.
Industry
Eligibility
18 Years and older
Enrollment
866 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Arlington Heights, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Oct 31, 2026, 9:21 AM EDT
Completed No phase listed Observational

Replication of the INSPIRE Trial in Healthcare Claims Data

NCT05179512
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Tiotropium, salmeterol-fluticasone
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 80 Years
Enrollment
98,278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 31, 2026, 9:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects Under Fed Conditions

NCT03424135
View directory record Official record
Conditions
Clinical Pharmacology
Interventions
Naproxen sodium and diphenhydramine hydrochloride soft capsules, Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve PM, BAY98-7111)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 31, 2026, 9:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study of Dronabinol Capsules 10 mg Under Fasting Conditions

NCT01380457
View directory record Official record
Conditions
To Determine Bioequivalence Under Fasting Conditions
Interventions
Dronabinol, Marinol
Drug
Lead sponsor
Par Pharmaceutical, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Oct 31, 2026, 9:21 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Stain and Plaque Removal Capability of Two Experimental Potassium Nitrate Dentifrices

NCT03267511
View directory record Official record
Conditions
Oral Hygiene
Interventions
5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica, 5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP, 5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica, 5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 31, 2026, 9:21 AM EDT
Active, not recruiting Not applicable Interventional

The Chocolate Touch Study

NCT02924857
View directory record Official record
Conditions
Peripheral Artery Disease (PAD), Ischemia, Intermittent Claudication
Interventions
Chocolate Touch, Lutonix Drug Coated Balloon
Device
Lead sponsor
TriReme Medical, LLC
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
15
States / cities
Gainesville, Florida • Miami Beach, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 31, 2026, 9:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.

NCT06673654
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib Topical Cream 1.5%, OPZELURA (Ruxolitinib) Cream, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years and older
Enrollment
476 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 31, 2026, 9:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subjects

NCT02059031
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK1265744 Reference formulation, GSK1265744 New formulation 1, GSK1265744 New formulation 2
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Oct 31, 2026, 9:21 AM EDT
Terminated Phase 2 Interventional Results available

MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma

NCT01973608
View directory record Official record
Conditions
Melanoma
Interventions
MSB0010445 (0.3 milligram per kilogram [mg/kg]), MSB0010445 (1.0 mg/kg), MSB0010445 (1.8 mg/kg), MSB0010445 (2.4 mg/kg), Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Oct 31, 2026, 9:21 AM EDT
Completed Phase 3 Interventional

Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT05986591
View directory record Official record
Conditions
COPD
Interventions
Test Product - Tiotropium Bromide Inhalation Powder 18 mcg, Spiriva Handihaler (Tiotropium Bromide) 18 mcg, Placebo
Combination Product
Lead sponsor
Xiromed LLC
Industry
Eligibility
40 Years to 75 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
24
States / cities
Los Angeles, California • Fort Myers, Florida • Gainesville, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 31, 2026, 9:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Volunteers to Establish the Bioequivalence of Two Different Manufacturers.

NCT01632449
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Test product, Reference product
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 31, 2013 · Synced Oct 31, 2026, 9:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study of Advil Dual Action Liquid Filled Capsules (125 mg/250 mg) Versus Advil Dual Action Caplets (125 mg/250 mg) and Bioavailability Assessment of Advil Dual Action Liquid Filled Capsules (125 mg/250 mg) and Advil Liqui-Gels (200 mg) in Healthy Adult Subjects

NCT06802185
View directory record Official record
Conditions
Pain
Interventions
ADA Liquid Filled Capsules (Test Product), ADA Caplets (Reference Product), Advil Liqui-gels (Reference Product)
Drug
Lead sponsor
HALEON
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 31, 2026, 9:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Assess the Bioequivalence of the 4mg Prototype Mini Nicotine Lozenge to the Reference Product (Nicorette) in Healthy Smokers

NCT03543137
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Nicotine Prototype Mini lozenge, Nicorette Mini Lozenge
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Oct 31, 2026, 9:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Protein-Prebiotic Wellbeing Study

NCT05303753
View directory record Official record
Conditions
Digestive Health, Quality of Life
Interventions
fermented dairy protein with prebiotic fiber
Other
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 35 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 31, 2026, 9:21 AM EDT